24.8 C
New York
Saturday, June 6, 2026

Tag: malignant cells

newssourceFORcompanyinformationcontent1marketreleases

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells 
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

SINGAPORE, July 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases...

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 
First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a...

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers | Valuates Reports

Anticancer Drugs Market is Segmented by Type (Cancer Immunotherapy, Targeted Therapy, Chemotherapy), by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer). BANGALORE, India, June...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMalignant cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers